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Actions of metformin and statins on lipid 
and glucose metabolism and possible benefit 
of combination therapy
Mariël F. van Stee1,3, Albert A. de Graaf1 and Albert K. Groen2,3*
Abstract 
Patients with diabetes type 2 have an increased risk for cardiovascular disease and commonly use combination 
therapy consisting of the anti-diabetic drug metformin and a cholesterol-lowering statin. However, both drugs act on 
glucose and lipid metabolism which could lead to adverse effects when used in combination as compared to mono-
therapy. In this review, the proposed molecular mechanisms of action of statin and metformin therapy in patients 
with diabetes and dyslipidemia are critically assessed, and a hypothesis for mechanisms underlying interactions 
between these drugs in combination therapy is developed.
Keywords: Type 2 diabetes, Metformin, Atorvastatin, Simvastatin, Combination therapy, Dyslipidemia, Glucose 
metabolism, Lipid metabolism
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Background
Type 2 diabetes mellitus (T2DM) and cardiovascular 
diseases are common medical conditions that are often 
found comorbid with each other. T2DM is a metabolic 
disorder characterized by increased plasma glucose con-
centration (hyperglycemia) caused by persistent insulin 
resistance, and progressive β cell failure. Insulin resist-
ance is a normal reaction of the body to cope with an 
excess of circulating triglycerides. Normally, food intake 
causes only a transient insulin resistance, but currently 
the excess of energy intake in humans in many regions 
of the world is almost constant causing sustained insulin 
resistance leading to T2DM often in combination with 
dyslipidemia.
Metformin is used as first line treatment of T2DM 
due to its primary pharmacological effect of controlling 
disturbed glucose metabolism [1]. Interestingly, despite 
its longstanding and widespread use, the molecular 
mechanism via which the drug acts is still a matter of 
considerable controversy as it additionally influences 
lipid/cholesterol pathways. Dyslipidemia (or diabetic 
dyslipidemia when diagnosed in T2DM patients) is 
an abnormality in lipid metabolism; i.e. quantitatively 
observed in abnormalities in blood lipids including 
increased triglycerides (TG) and low-density lipo-
protein (LDL-C) and a decreased high-density lipo-
protein cholesterol (HDL-C) concentration [2]. These 
disturbances are established risk factors in the devel-
opment of atherosclerosis [3]. Metformin treatment 
double dose (500–750 mg/day) given to T2DM patients 
showed after 12 weeks a decreased central blood pres-
sure suggesting a beneficial influence on cardiovascular 
disease [4]. Table 1 (Supplementary) shows recent arti-
cles related to diabetic dyslipidemia. Statins are pre-
scribed as first choice treatment for (T2DM) patients 
with dyslipidemia, because of their impressive LDL-C 
lowering effects. Dyslipidemia and insulin resistance 
are potential risk factors for myocardial infarction [5]. 
Therefore, it is also important to initiate statin therapy 
in diabetic patients without known cardiovascular dis-
ease [5]. Paradoxically long-term statin therapy when 
given as monotherapy to dyslipidemic patients is asso-
ciated with increased incidence of T2DM [6, 7]. Both 
metformin and statins thus act on glucose—as well 
as lipid metabolism which is why metformin–statin 
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combination therapy is prescribed to many T2DM 
patients. However, the therapeutic effects of different 
doses of statin and metformin given in combination 
have not been thoroughly and systematically investi-
gated. Since both drugs act on glucose as well as lipid 
metabolism, it is important to understand in detail the 
interactions between metformin and statin action on 
metabolism to be able to design treatments with opti-
mal safety/efficacy profiles
The aim of this article is therefore to provide insight 
in the molecular mechanism of statin/metformin inter-
action which can help to determine an optimal dosing 
strategy of both drugs.
Antidiabetic drug metformin and the potential 
mechanisms by which it may affect lipid 
metabolism
Metformin, discovered in 1922, came on the market 
as late as 1979 [8]. It belongs to the biguanide class of 
drugs, and is a derivative from guanidine found in Galega 
officinalis. Metformin is available in different formula-
tions including immediate-release metformin, extended-
release metformin [9], and delayed-release metformin 
[10]. The latter two forms were developed to expand the 
absorption of metformin along the gut (Table 2). Admin-
istration of metformin 30  min before a meal showed 
highest therapeutic efficacy in lowering postprandial 
hyperglycemia [11].
Table 1 Overview of areas and focus of recent review articles about diabetes dyslipidemia and the corresponding focus 
area for each review is given
Area Focus References
Pathophysiology No specific focus/general Besseling and Hutten [153], Cederberg et al. [154], Checade et al. [155], Feingold 
and Grunfeld [156], Jaiswal et al. [157], Ng [158], Soran et al. [159], Schofield et al. 
[160], Verges[161], Wang et al. [162], Wu and Parhofer [2]
Intestine Arca [163], Tomkin and Owens [164]
Liver Arca et al. [165], Perry et al. [166], Taskinen and Boren [167]
Relation IR and lipids – Pagidipati et al. [168], Parhofer [169], Patel et al. [170], Perry et al. [166]
CV risk – Wang et al. [162]
Pharmacotherapy/treatment Treatment of dyslipidemia Cederberg et al. [154], Checade et al. [155], Dake and Sora [171], Halcox and Misra 
[172], Ng [158], Paneni and Cosentino [173], Schofield et al. [160], Szalat et al. 
[174], Wu and Parhofer [2]
Effects drugs on lipid and 
glucose metabolism
Ferrannini and DeFronzo [175], Soran et al. [159]
Complications – Balakumar [176], Chen and Tseng [177], Leon and Maddox [178], Paneni et al. [179]
Table 2 Different formulations and the corresponding relevant characteristics of the oral drug metformin (information 
from [180])
qd once a day, bid twice a day
Metformin formulation Dose Cmax (ng/ml) tmax (h) AUC mean (ng*h/ml) Properties Refs
Immediate release (IR) 1000 mg bid 1328 3.5 18,710 Rapid gut absorption





Extended release (ER) [181] 2000 mg qd 1688 5.1 16,990 Two-phase approach tablet using 
polymers
Prolonged gut absorption (duodenum 
and jejunum)
90% absorption within 10 h
[9, 182]
Delayed release (DR) [183] 500 mg bid/1000 mg bid 905/607 9/9 9010/6160 Enteric coated (polymers) core tablet
Release of metformin by pH of 6.5 
(distal small intestine)
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Chemical characteristics
Metformin hydrochloride has a molecular weight of 
165.6 g/mol and contains 4 hydrogen bond donors and 1 
hydrogen bond acceptor. There is only a limited under-
standing of the physicochemical properties of metformin 
in solvent [12]. Metformin hydrochloride shows two dis-
tinct pKa values referring to different protonated forms 
of metformin (Table 3). The pKa values were reported as 
2.8 and 11.6 [13], but using a more accurate pH determi-
nation as 3.1 and 13.8 [14].
Intracellular localization
As is evident from Table 3, metformin is present for over 
99% in the monoprotonated form in all tissues of the 
body except the stomach. The charge on the molecule 
precludes passive diffusion across lipid bilayers. To be 
able to evaluate the interaction of metformin with its 
putative targets it is important to know the intracellular 
and intraorganellar concentration. However, these data 
are difficult to obtain because of the difficulties in sub-
fractionation of the cell in its different compartments 
(cytoplasm, mitochondria, nucleus, etc.). The sparse 
data reported, indicate that metformin is mostly dis-
tributed in the cytosolic fraction (~ 70%) of rat hepato-
cytes compared to mixed membranes (12%), nucleus 
(~ 5%), and mitochondrial and lysosomal fractions (8%) 
[15]. A low binding affinity of metformin to mitochon-
drial membranes was seen, perhaps because of the two 
methyl groups of metformin [15], but perhaps also due 
to the used fractionation technique [16]. However, the 
mitochondrial membrane potential may promote entry 
to the positively charged metformin [17], which will then 
concentrate inside the negatively charged mitochondria 
[18]. Modelling of the metformin distribution and valida-
tion confirmed the presence of high concentrations of the 
drug in the mitochondria and the endoplasmic reticulum 
(ER), dependent on the membrane potential [19].
Distribution of metformin concentrations over organs, 
tissues, and plasma
Metformin is able to (in)directly interact with many 
enzymes [e.g. mitochondrial electron transport chain 
complex I, AMPK, glycerol 3-phosphate dehydroge-
nase (mGPD)], which lead to a large diversity of pos-
sible effects of the drug. When scrutinizing literature 
on metformin effects, one needs to consider that in 
many studies supraphysiological concentrations of 
metformin were used [20]. The reported cellular sites 
of actions and effects thus may not reflect the in  vivo 
situation when metformin is given to T2DM patients. 
Normally, the therapeutic window of metformin in 
plasma is between 1 and 50 μM [21]. Table 4 presents 
an overview of metformin concentrations as observed 
in  vivo in organs/tissues of humans, mice, and rats 
upon administration of doses that lie in the range of 
therapeutic applications in humans. Accumulation of 
metformin occurs majorly in the intestine, but also in 
the stomach, liver, kidney and to a lesser extent in mus-
cle. The accumulation of metformin in intestine and 
stomach is not surprising in view of the fact that these 
organs are most exposed to high concentrations of met-
formin. A recent radiotracer study confirmed the high 
metformin levels in these organs [22]. These concentra-
tions are at least tenfold higher than metformin con-
centrations in the liver, indicating that the intestine is 
Table 3 Percentage of fractional ionization of metformin after oral administration in different organs/tissues calculated 
using the Henderson–Hasselbalch equation
The pH in the different organs/tissues/plasma leads to different forms of metformin. Neutral metformin, which is a base, will only be dominant at very high pH. The 
monoprotonated conversion of metformin with a stabilized cation (equally distribution between the nitrogen atoms) occurs in a neutral environment (pH ≈ 7). 
Biprotonation of metformin appears by a decreasing pH value
Human body pH Metformin chemical form Absorption
[B] [HB+] [H2B
2+]
Oral cavity 7 0 99.99 0.01 –
Stomach 2 0 7.36 92.64 10%
Jejunum + ileum 8 0 100 0 60%
Duodenum 6.25 0 99.93 0.07 20%
Plasma/liver 7.4 0 99.99 0.01 –
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probably an important site of action. In fact, the effects 
of metformin in the intestine may be rather different 
than the effects in the liver.
For the purpose of this review, we will concentrate on 
the organs considered to be most relevant for interaction 
of metformin with glucose and lipid metabolism, i.e. the 
intestine because of the high metformin concentrations, 
the liver because of the organ’s central role in linking 
glucose and lipid metabolism, and the pancreatic β cells 
which secrete insulin and play a key role in the regulation 
of glucose metabolism. Since metformin concentrations 
differ between intestine, liver and β cells, different organ-
specific effects may be expected.
Intestinal absorption
After oral administration, metformin is transported in 
the small intestine across the apical membrane into the 
enterocytes via several transporter proteins, of which 
the plasma monoamine transporter (PMAT; SLC29A4), 
organic cation transporter 1 (OCT1; SLC22A1) and 
serotonin transporter (SERT; SLC6A4) are considered 
to be the most likely candidates [23, 24]. Metformin is 
also a substrate for the thiamine transporter THTR-2 
(SLC19A3), with a  Km value of 1.15 mM [25]. This binding 
affinity is comparable with the  Km of PMAT (1.32 mM) 
for metformin [26]. THTR-2 is highly expressed in the 
intestine, and primarily transports vitamin B1. Poly-
morphism in the human OCT1 gene has been reported 
and could cause a reduced transport of metformin lead-
ing to the development of metformin intolerance [27]. 
In Caco-2 cells there is no evidence for a role of apical 
organic cation transporter 3 (OCT3; SLC22A3) in the 
uptake of metformin [23]. Transporters mediating met-
formin efflux from the enterocytes have not been une-
quivocally identified. The OCT1 has been suggested, 
but it is not clear whether this transporter could have a 
dual localization both at the apical and basolateral mem-
brane of the enterocytes [20, 28]. The recently published 
“sponge” hypothesis, based on experiments on caco-2 
cells, suggests that there is no carrier mediated trans-
port to the bloodstream. Rather, metformin accumulates 
in the cell until the luminal concentration is less than 
the concentration in the enterocytes, whereupon-it is 
pumped/leaking out back into the lumen and will travel 
via paracellular transport to the blood or will be taken 
up again by cells [29]. This hypothesis has been partly 
confirmed in experiments with  C11-labeled metformin 
followed by positron emission tomography. These experi-
ments revealed a low capacity of basolateral membrane 
transport activity in humans resulting indeed in accumu-
lation in the cell when there was a higher concentration 
of metformin in the lumen compared to in the cell [22].
Mechanisms of metformin action in the intestine
The concentration of metformin in human jejunum has 
been shown to be 30- to 300-fold greater than in plasma 
(Table  4), again demonstrating accumulation of met-
formin in the intestinal mucosa [30]. Because of this 
remarkably high concentration it seems logical to assume 
that all known metformin targets present in enterocytes 
are addressed.
To simplify, we grouped the resulting effects into: 
decreased lipoprotein synthesis, neural reduction of 
endogenous glucose production, and increased glucagon-
like peptide-1 (GLP-1) production.
Decreased lipoprotein synthesis
Dysregulation of intestinal lipoprotein metabolism is 
often seen in T2DM patients [31–33]. The high con-
centrations of insulin found in T2DM patients may be 
responsible for this phenomenon [34]. Lipogenic gene 
expression, involved in de novo lipogenesis, is regu-
lated by the sterol regulatory element-binding protein-
1c (SREBP-1c), which is highly expressed in the upper 
villus of the jejunum and ileum [35]. SREBP-1c in the 
intestine is positively regulated by insulin and negatively 
by AMPK, and is able to upregulate enzymes, such as 
acetyl-CoA carboxylase (ACC1) and fatty acid synthase 
(FAS), which are involved in denovo fatty acid synthesis 
[36, 37]. Metformin (2300  mg/day) is able to decrease 
intestine-derived TG-rich lipoproteins measured in 
plasma (~ − 50% chylomicrons and ~ − 20% chylomicron 
remnant lipoprotein fractions) in T2DM patients [34]. 
Figure 1 shows the possible cellular targets of metformin 
in enterocytes based on the literature discussed here. 
Metformin treatment of morbidly obese T2DM patients 
induced a small decrease in mRNA expression of SREBP-
1c, ACC1, and apo A-IV (involved in the secretion of chy-
lomicrons), leading to a slightly improved intestinal lipid 
homeostasis [33]. Insulin positively regulates synthesis of 
intestinal apo A-IV as well as secretion [38], which may 
cause an increase of this protein at the high insulin lev-
els in the presence of insulin resistance. Experiments in 
animal models confirmed the possible interaction of met-
formin with proteins and enzymes involved in triglycer-
ide and apo B synthesis.
In addition to the effects discussed above, a decreased 
chylomicron concentration could also be caused by an 
elevated GLP-1 concentration in the intestine (induced 
by metformin; see “Increased GLP-1 production”) by 
reducing apo B-48, the triglyceride availability, and chy-
lomicron secretion [39, 40], although this is not consid-
ered in [33–35, 41].
Summarizing, metformin treatment impacts impor-
tantly on lipoprotein synthesis in the intestine, but the 
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molecular mechanism is not yet fully clear and requires 
further investigation.
Neuronal reduction of EGP
The liver and kidneys are the major organs responsible 
for gluconeogenesis from amino acids or glycerol. How-
ever, pioneering work of the group of Mithieux showed 
that also the human small intestine expresses consider-
able activity of the gluconeogenic gene [glucose 6-phos-
phatase (G6Pase)], and may therefore contribute to 
endogenous glucose production (EGP) [42]. Intestinal 
gluconeogenesis may play a role in the gut-brain axis. 
In the post absorptive state, amino acids from the meal 
are used as a substrate for intestinal gluconeogenesis. 
This glucose enters the portal vein, where it binds to the 
sodium-glucose cotransporter 3 (SGLT3). This trans-
porter is activated and signals to the hypothalamus in 
the brain which indicates the liver to decrease hepatic 
glucose production [43]. Basal intestinal gluconeogenesis 
may contribute 5–7% (standard meal) or 20–25% (pro-
tein-enriched meal) of total EGP [44] in mice. Whether 
these estimates can be translated to the human situation 
is not clear yet.
The question arises whether metformin interacts with 
intestinal gluconeogenesis. Activities of key enzymes [e.g. 
phosphoenolpyruvate carboxykinase (PEPCK), hexoki-
nase] contributing to small intestine glucose metabo-
lism were not affected during one-week metformin 
treatment (50  mg/kg/day) in high-fat fed rats [45]. Yet, 
intestinal glucose uptake and intestinal glucose release 
were increased, and the overall endogenous glucose pro-
duction was decreased compared to controls (Fig.  2). 
Another study showed that metformin treatment induces 
alterations in the gut microbiome in T2DM patients [46]. 
This has been reported to increase butyrate and propion-
ate production, possibly via modification of the host lipid 
absorption [46, 47], which may then support intestinal 
gluconeogenesis [46].
The last few years, the small intestine has come into 
view as the prime target of metformin. Experiments with 
infusion of the drug in the proximal small intestine (50 
or 200  mg/kg; 50  min), of obese and diabetic rats [48] 
Fig. 1 Summary of the effects of metformin on intestinal lipoprotein synthesis in different experimental studies. Key events are the positive 
regulation of AMPK and GLP-1, from where a spectrum of changes in the fatty acid and TG synthesis, and chylomicron production are observed that 
effectively result in decreased intestinal lipoprotein synthesis. Arrows represent stimulation, and T-shaped symbols represent inhibition
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indicated that the hepatic glucose production decreased 
via an AMPK-GLP-1 receptor (GLPR)-protein kinase 
A (PKA)-dependent neuronal route. The heterotrimer 
AMPK is a serine/threonine kinase constituted from a 
catalytic α-subunit and regulatory β- and γ-subunits. The 
protein plays and important regulatory role in cellular 
energy metabolism [49]. Several pharmacological com-
pounds (e.g. metformin), natural compounds (rooibos, 
berberine), hormones (adiponectin, leptin, IL-6), and 
physiological processes (exercise, fasting, caloric restric-
tion) activate AMPK activity [50]. Activated AMPK has 
pleiotropic effects on energy metabolism improving insu-
lin resistance and diabetes type 2 [51]. In the proposed 
intestinal-neuronal pathway, metformin activated intes-
tinal AMPK which interacts with the GLPR and PKA, 
leading to stimulation of a neuronal signal via the nervus 
vagus to the brain. According to this hypothetical route 
in the brain, the N-methyl-d-aspartate (NMDA) recep-
tors located in the nucleus tractus solitarius (contribute 
to autonomic regulation) receive this neuronal signal, 
and react by sending a signal via the hepatic vagus to the 
liver where it decreases hepatic EGP. Additionally, it was 
hypothesised that metformins glucose lowering effects 
on short term (i.e. first drop in glucose concentration 
after a meal) might be related to intestinal processes, 
while long-term effects might be dedicated to hepatic 
processes [48].
Increased GLP‑1 production
Production of GLP-1 occurs mainly in the enteroen-
docrine L cells located mostly in the distal part of the 
small intestine and in the colon, while it can also be 
released by α-cells from the pancreas [52]. The regu-
lation of GLP-1 production is complex and involves a 
combination of nutrient, hormonal and neural stimuli 
[53]. Increased fasting total and active GLP-1 as well 
as circulating total GLP-1 concentrations have been 
measured in obese (T2DM) patients on metformin 
treatment [54–56], Different mechanisms have been 
proposed to explain this increase [57]. An AMPK-
dependent pathway, an AMPK-independent pathway, 
and a bile acid mediated pathway, have been proposed 
to explain the effects of metformin on GLP-1 secretion 
(Fig. 3) as discussed below.
Several studies have suggested mechanisms responsible 
for the increased GLP-1 secretion observed during met-
formin treatment in which AMPK plays a prominent role 
[48]. In the human small intestine, AMPK is present in 
the apical part of the small intestine, mainly at the lumen 
villus absorptive cells (i.e. below brush border and in 
stromal cells) and fulfils important functions in metabolic 
pathways, leading to favourable effects during metformin 
treatment [41]. Whereas in rats on metformin treatment 
(50 or 200 mg/kg) the need of duodenal AMPK in order 
to activate GLPR was confirmed [48].
Fig. 2 Summary of the effects of metformin in the intestine (small intestine and duodenum) that cause glucose-lowering effects by reducing the 
hepatic EGP
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Non‑AMPK dependent pathways Other non-AMPK 
dependent pathways exist, for instance, it is argued in [58] 
that effects on GLP-1 production by metformin (1 mM in 
NCI-H716 human intestinal cells and/or 12.5 mg/kg body 
weight in mice) were not mediated through AMPK signal-
ling. Instead, [58] demonstrated that increased expression 
of precursors of GLP-1 on L-cells is regulated through 
increased glucose entering in the cell via SGLT1 located in 
the brush border membrane of the lumen. Increased glu-
cose uptake by SGLT1 was a consequence of an increased 
expression of SGLT1. Genes involved in glycolysis/TCA 
cycle/electron regulation cause closing of the  K+ chan-
nel and opening of the  Ca2+ channel. The increased  Ca2+ 
flux activates the calcium–calmodulin dependent kinase 
2 (CAMK2) and cAMP response element binding protein 
(CREB) resulting in the activation of the insulin signalling 
pathway [insulin receptor substrate 2 (IRS2), phospho-
inositide 3 kinase (PI3K), and protein kinase B (AKT)], 
and consequently inhibition of glycogen synthase kinase 
3 (GSK-3b). This causes b-catenin, a protein involved in 
transduction of signals to the nucleus, to move to the 
nucleus where it merges with transcription factor 7-like 
2 (TCF4L2), leading to an increased proglucagon activ-
ity (a precursor of GLP-1), and GLP-1 production [58]. 
However, in a different study only a slightly increased 
expression of b-catenin and no effect on the expression of 
TCF7L2 was observed in the nucleus of NCI-H716 human 
intestinal cells during metformin treatment (1 mM) [59]. 
The precursors of GLP-1, proglucagon and prohormone 
convertase 3 were also upregulated in this study, causing 
elevated secretion of GLP-1 [59]. GLPR on the afferent 
vagus nerve triggers a gut-brain-liver network, which may 
decrease the hepatic glucose production [48].
Metformin might also indirectly act on GLP-1 secretion 
via the modulation of bile acids in the intestine, for which 
[55] summarized two potential mechanisms. Firstly, met-
formin inhibits the intestinal apical sodium-dependent 
bile acid transporter (ASBT), causing bile acids (BA) to 
accumulate in the intestinal lumen. Therefore, the apical 
G protein-coupled bile acid receptor 1 (TGR5) is stimu-
lated which will cause an increased secretion of GLP-1. 
Secondly, because of the inhibition of ASBT the concen-
tration of BA in the illeoocyte will decrease, resulting in 
decreased activation of the nuclear farnesoid X recep-
tor (FXR). Lack of FXR activation results in inhibition 
of the glycolytic pathway and activates the expression of 
Fig. 3 Summary of the effects of metformin discussed in the text that cause increased intestinal GLP-1 secretion
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proglucagon and intracellular ATP, leading to increased 
GLP-1 production and secretion [60].
Metformin decreases bile acid concentration in enterocytes 
and modulates the gut microbiota The concentration of 
bile acids in the intestine is the result of multiple processes 
involved in the enterohepatic circulation (~ 6 times daily) 
that consists of: release of bile by the hepatocytes into 
the bile canaliculi, the storage of bile in the gall bladder 
where it is concentrated, release of bile after consuming a 
meal, flux of bile into the duodenum, the reabsorption of 
bile acids by the sodium-dependent intestinal ASBT, pas-
sive diffusion mechanisms to the portal vein, and the re-
uptake by hepatocytes.
Hepatobiliary transport (transport from the sinusoid to 
the bile) of metformin in humans, rats and mice, is neg-
ligible indicating that uptake of metformin in the small 
intestine occurs only by a first pass mechanism [22, 61, 
62]. Metformin (> 1000 mg/day) is able to inhibit bile acid 
absorption in the intestine, leading to a decreased serum 
bile acid concentration [55] and an increased faecal bile 
acid excretion in T2DM patients [63]. The altered metab-
olism of bile acids by metformin may also be the reason 
why metformin influences the composition of the gut 
microbiome. This has developed into an important sub-
ject of research after high throughput sequencing plat-
forms became available, and altered metabolic functions/
composition of the microbiota were observed in obese/
diabetic patients [64]. The gut microbiome composition 
is associated with dyslipidemia and insulin resistance 
[65]. Since the gut bacteria are important in bile acid 
metabolism and thereby may influence host metabolism 
via the nuclear hormone receptor FXR and TGR5 signal-
ling pathways [66] part of the metformin effects on host 
metabolism may be secondary via this route. Recently, 
the effects of metformin on the gut microbiota com-
position in T2DM patients were investigated [67]. The 
composition was changed, including an increased abun-
dance of Akkermansia muciniphila (related to metabolic 
health [68]) and multiple bacteria involved in the short-
chain fatty acid (i.e. butyrate, propionate) production. 
De la Cuesta-Zuluaga et  al. suggest that the improved 
metabolic health is associated with a stronger intesti-
nal mucosal barrier caused by the affected bacteria [67]. 
Diversity of the microbiota may also contribute to the 
different observations seen in T2DM treated with met-
formin [69]. The effect of metformin on gut microbiota 
composition was confirmed in a recent randomised con-
trolled trial in T2DM patients [47]. Transplantation of 
fecal microbiota derived from metformin-treated sub-
jects to germ-free mice improved glucose tolerance 
compared to mice that received fecal microbiota from 
placebo-treated controls. This indicates that changes in 
gut microbiota induced by metformin treatment medi-
ate part of the beneficial effects of this drug on glucose 
homeostasis [47]. Alterations in bile acid metabolism 
may partly explain the effects.
Mechanisms of metformins action in the liver
Metformin navigates to the liver via the portal vein 
and is taken up predominantly by OCT1 [70] as well as 
by THTR-2 [25]. The main mechanisms of metformin 
involved in decreasing the endogenous glucose produc-
tion and plasma glucose have all been extensively and 
critically reviewed elsewhere [71–73]. In this review, the 
effects of metformin on the lipid metabolism are high-
lighted, thereby creating a special focus on the effects on 
lipids related to the activation of AMPK by metformin. 
Figure  4 shows the specific interactions of metformin 
resulting in an improved lipid metabolism.
AMPK‑dependent metformin effects on HMG‑CoA reductase
Metformin activated AMPK is able to modulate choles-
terol synthesis as well. Phosphorylation of 3-hydroxy-
3-methyl-glutaryl-coenzyme A reductase (HMGCR) 
will decrease cholesterol biosynthesis [74]. Besides the 
phosphorylation of the protein downregulated mRNA 
levels (≈ 70%) of HMGCR and HMG-CoA synthase 
(HMGCS) were detected in rat FaO hepatoma cells 
treated with 2*10−3 and 5*10−3 M metformin [75]. This 
drastic decrease was, however, not observed when met-
formin was administered in a lower more physiologi-
cal relevant concentration (1*10−3 M). Treatment of rat 
primary hepatocytes with metformin (0.5–5*10−4 M) 
induced inhibition of HMGCR and HMGCS mRNA 
expression [76]. A not significant decrease of HMGCR 
activity of human cultured fibroblast was observed with 
metformin treatment (4226 ± 413, no metformin vs. 
4082 ± 396  pmol/h per mg, 5*10−5 M metformin) [77]. 
In another study, the cholesterol biosynthesis rate from 
 [3H] acetate, but not from  [14C] mevalonate, was sup-
pressed by 11% following murine macrophage cell incu-
bation with 2*10−3  M metformin, respectively [78]. 
This indicates that metformin is able to slightly inhibit 
macrophage HMGCR, even though relatively high 
concentrations were chosen. Metformin treatment of 
mice decreased both triglyceride (~ − 35%) and LDL-C 
(~ − 30%) concentrations in plasma [79]. Interestingly, 
a study in 1983 showed the differences of HMGCR in 
the liver and intestine of diabetic rats before and after 
250  mg/kg metformin treatment [80]. Hepatic HMGCR 
was not affected by metformin treatment, while intes-
tinal HMGCR showed a decrease in activity of ~ 62%. 
The Acyl-CoA cholesterol acyltransferase (ACAT) 
involved in the catalysis of cholesterol esters showed 
as well decreased activity (~ − 35%). This cholesterol 
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lowering effect in the intestine may lead to beneficial 
effects on cholesterol metabolism, and further supports 
the hypothesis that the intestine is an important target 
organ of metformin. In a nutshell, metformins action on 
HMGCR is weak in hepatocytes, and it is plausible that 
other pathways are involved in achieving the lipid lower-
ing effects of metformin.
Other mechanisms of metformin effecting the lipid 
metabolism
Metformin shows beneficial effects on the glucose and 
lipid metabolism [81], even though the pathways and 
the corresponding strengths are not fully understood. 
Part of the variation in metformin efficacy may be due to 
the presence of responders and non-responders to met-
formin treatment [82, 83], racial and ethnic background 
[84], and personal variation in the adaptation of met-
formin treatment. In the literature, different pathways are 
suggested that could contribute to the positive effects of 
the drug the lipid metabolism (Fig. 4).
A pathway inducing reduction of LDL cholesterol has 
been proposed by Sonne et al. [85] and is as follows. Inhi-
bition of the intestinal absorption of bile acids by met-
formin causes an increased synthesis of bile acids in the 
liver, and cholesterol is used for this process [86], thereby 
causing a decreased amount of cholesterol in the hepato-
cytes. Upregulation of the LDL-C receptor may increase 
the uptake of lipoproteins, to restore a sufficient level of 
cholesterol in the liver. Hereby, the LDL-C concentration 
and plasma total cholesterol concentrations may indi-
rectly decrease by the action of metformin. However, it 
should be noted that this mechanism could account for 
only marginal effects. Major increases in bile acid excre-
tion induced by treatment of hyperlipidemic patients 
with the bile acid sequestrant cholestyramine for 7 years 
showed only a 13 and 20% decrease in plasma total cho-
lesterol and LDL-C levels [87].
An interesting hypothesis of anti-atherosclerotic activ-
ity by metformin was introduced [88]. It was found that 
metformin increased expression of the fibroblast growth 
factor (FGF21) in hepatocytes, likely by the activation of 
AMPK [89], thereby stimulating expression of adenosine 
triphosphate binding cassette (ABC) transporters A1 
and G1. This may increase cholesterol efflux from mac-
rophages and decrease development of atherosclerotic 
plaques [88]. FGF21 is an important metabolic regula-
tor, which may serve as a protection response against 
glucose-lipid disorders. The effects of metformin on 
FGF21 need further investigation, since it was reported 
that plasma FGF21 levels in humans with T2DM [90] are 
decreased after metformin treatment (opposite to the 
description in the hypothesis).
Another alternative pathway via which metformin may 
influence lipid metabolism in T2DM patients was pro-
posed in [91]. Metformin induced activation of AMPK 
in the liver inhibited the SREBP-1c. The SREBP-1c gene 
was also found to be downregulated by metformin in 
another study [79]. This downregulation activated fatty 
Fig. 4 Summary of the effects of metformin in the liver that cause an overall improved lipid metabolism by reducing triglycerides, LDL-C, and total 
cholesterol
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acid desaturase 1(FADS1) and FADS2, which reduced 
arachidonic acid levels [92]. This reduction may cause 
increased membrane fluidity, thereby increasing LDL-C-
receptor recycling and a reduction in the LDL-C levels 
[92].
Downregulation of SREBP1c affects many lipogenic 
genes. The acetyl-CoA carboxylase (ACC), catalysing the 
malonyl-CoA biosynthesis, was inhibited by AMPK dur-
ing metformin exposure (0.5, 1, 2  mM; 27  h) in human 
hepatoma HepG2 cells [93], leading to a reduced amount 
of triglycerides. The gene fatty acid synthase (FASN) 
and SREBP-1C were also downregulated [75]. This indi-
cates that the lipogenesis pathway may also be affected 
by metformin resulting in decreased fatty acids and 
triglycerides.
Figure  4 Summary of the effects of metformin in the 
liver that cause an overall improved lipid metabolism by 
reducing triglycerides, LDL-C, and total cholesterol.
(In)‑direct effects of metformin on β cells
Clearly a decreased β cell mass is an important factor in 
the development of T2DM. Gluco- and lipotoxicity (high 
glucose and FFA) induce damaging effects on β cells (e.g. 
decreased insulin secretion and β cell mass) [94]. It is 
therefore of interest to consider possible beneficial effects 
of metformin on β cell function. Research in this field is 
growing.
The enzymes lipase and amylase are secreted by the 
pancreas and are often measured to monitor the condi-
tion of the pancreas. There were no changes observed 
in lipase, amylase, and the pancreas volume when met-
formin (1950  mg/day) was given to T2DM patients for 
24 weeks [95] suggesting that metformin does not repair 
damaged β cells. In this study, the product of dynamic, 
static and total β cell responsiveness and insulin sensi-
tivity, also called the disposition indices  (DId,  DIs, and 
 DItotOB) calculated by an oral minimal model [96], 
showed that metformin (1000–1500  mg twice daily) for 
2  weeks caused a significant increase in  DId,  DIs, and 
 DItotOB, a decreased homeostasis model assessment of 
insulin resistance (HOMA-IR), and an increased insu-
lin sensitivity, majorly whole-body insulin sensitivity 
[97]. In contrast, another study showed no significant 
changes, which may perhaps occur because of the dif-
ferent personalized responses to metformin resulting 
in high standard errors [95]. The β cell responsivity was 
not altered in both studies and it was also suggested 
that metformin gives a more robust response to a high-
fat mixed meal. This is also confirmed when treatment 
of metformin (1.45*10−5  M) showed to prevent damag-
ing effects when human pancreatic islets were incubated 
with FFAs by restoring the insulin secretion dynamics 
[98]. Summarizing, metformin showed to increase the 
insulin sensitivity, but not β cell function.
Metformin was reported to exert beneficial effects in 
INS-1E cells (cell line which displays characteristics of 
the β cell). When these cells were exposed to 0.5  mM 
metformin for 24  h an increase in AMPK phosphoryla-
tion, a 30% reduction of SREBP-1C protein expression, 
a 80% increase of GLPR protein levels, and increased 
insulin promoter factor 1 (PDX-1) protein levels were 
observed [99]. The increase in AMPK phosphorylation 
may suppress c-jun N-terminal kinase (JNK) and p38 
MAPK, resulting in reduced β cell apoptosis (2*10−3 M 
metformin INS-1E cells) [100]. However, in another 
study, metformin showed no effects on β cell survival nor 
β cell death in INS-1 cells, and it was found that GLP-1 
(through a PKA and PI3K pathway) is able to reduce 
apoptosis [101]. As discussed previously, metformin 
treatment showed increased GLP-1 levels from the intes-
tine, and this may explain the finding in the β cells.
Metformin treatment may also effect the compound 
nitric oxide (NO) and NO synthase (NOS) system, which 
play a significant role in β cell functioning and viability 
[102]. There is the neuronal constitutive NO synthase 
(ncNOS) which is associated with the mitochondria and 
insulin secretory granules, while inducible NOS (iNOS) 
located in the cytoplasm contributes to β cell failure 
during gluco- and lipotoxicity [102, 103]. Metformin 
(20*10−3 M) treatment had no effect on the NO-NOS 
system and insulin secretion in human and murine islets 
incubated at 7  mM glucose for 60  min [104]. However, 
metformin showed significant reduced ncNOS, iNOS, 
and total NOS activities, and slightly increased insulin 
secretion when the islets were incubated at 20 mM glu-
cose for 60 min [104]. Metformin (0.5*10−3 M) prevents 
glycogen accumulation in INS-1 cells incubated with 
25 mM glucose [105].
Summarizing, the available literature suggests that 
metformin ameliorates the damaging effects of high glu-
cose and FFA in β cells, and that the NO-NOS system 
may play a role in regulating the insulin secretion. Studies 
to investigate the effects of metformin on β cells in more 
detail are ongoing [106].
Potential mechanisms by which lipid lowering 
statins may affect glucose metabolism
Introduction
Statins are a class of drugs that decrease plasma choles-
terol levels and are prescribed as first choice to patients 
suffering from cardiovascular disease [107]. Simvasta-
tin and atorvastatin are often given as a first choice to 
patients with cardiovascular risk factors/cardiovascular 
disease. Low dose (20 mg/day) atorvastatin therapy given 
to patients with myocardial infarction showed improved 
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lipid, adipokine, and pro-inflammatory markers and 
decreased insulin resistance while higher dose (40  mg/
day) of atorvastatin showed hyperglycemia, increased 
leptin levels and ghrelin deficiency [108, 109]. A meta-
analysis observed that both intensive and non-intensive 
statin therapy may negatively influence glucose metabo-
lism resulting in around 9% increased risk of developing 
new onset T2DM [110]. Recently, it was discovered that 
the reduction in LDL-C by statins is an important indi-
cator of increased T2DM risk [111]. A LDL-C reduc-
tion between 30 and 40% induced a 13% increased risk 
of incident diabetes, the risk increasing to 29% with a 
40–50% LDL-C reduction [111]. Genetic factors and/or 
age-related factors could as well lead to the development 
of T2DM during statin treatment.
In this review, the focus is to investigate the effects of 
statins on glucose metabolism. We focus on liver and 
pancreas because of their important role in glucose 
metabolism. However, statins may also act their worsen-
ing effect on glycemic control via other organs (intestine) 
and tissues (muscle and adipose tissue).
Effects of statins on the endogenous glucose production 
in the liver
Several mechanisms possibly involved in the effect of 
statins on glucose metabolism are summarized below 
and in Fig. 5.
A proposed statin signalling pathway that stimulates 
EGP by activation of gluconeogenic genes was discovered 
in human liver cells [112]. Statin activates the pregnane 
X receptor (PXR) in the cytoplasm. PXR exerts a num-
ber of functions, such as the stimulation of the expres-
sion of proteins involved in removal of xenobiotics, 
and regulation of hepatic glucose and lipid metabolism 
[113]. PXR binds to the serum/glucocorticoid regulated 
kinase 2 (SGK2) which stimulates dephosphorylation of 
protein phosphatase 2CA (PP2CA) [112]. As a result, 
PXR together with the dephosphorylated SGK2 move 
to the region where gluconeogenic genes are located in 
the nucleus. These regions are called the PXR–SGK2 
response elements (PSRE) and an insulin response 
sequence region (IRS). PXR, SGK2 together with the 
nuclear retinoid X receptor (RXR) bind to these regions 
and thereby activate PEPCK1 and G6Pase [112]. This may 
result in an activation of EGP. Additionally, increased 
expression of PEPCK1 and G6Pase is observed through 
activation of an autophagic flux. Autophagy is a regulated 
destructive process of cellular elements and is upregu-
lated for example during starvation, ER stress, or intra-
cellular stress [114]. Contradictory results were found 
in a different study, where neither PEPCK1, G6Pase, nor 
EGP were affected in HepG2 cells treated with atorvasta-
tin (1 and 10 μM) [115].
In vivo experiments investigating the effects of sta-
tin treatment on glucose metabolism in T2DM patients 
showed no remarkable effects on EGP. Basal EGP 
in T2DM patients treated with atorvastatin (10  mg; 
12 weeks) [116] or simvastatin (80 mg/day; 8 weeks) [117] 
showed no changes. However, the EGP measured during 
clamp (isoglycaemic hyperinsulinaemic) conditions after 
12 weeks of statin treatment was slightly increased com-
pared with the baseline value in [116], but not in [117].
Summarizing, an increase of EGP induced by statins 
is not obvious from the above-mentioned studies per-
formed in statin-treated T2DM patients, while it is 
observed in in  vitro experiments. Therefore, it may be 
that the effects of statins on EGP are minor.
Effects of statins in the β cell
In the literature, many statin-effected processes are 
described that may contribute to a decreased insulin 
secretion in the β cell, possibly contributing to the pro-
gress of T2DM (Fig.  6). One of these directly affected 
processes are the upregulation of LDL-C receptor seen 
upon inhibition of HMG-CoA reductase, which results in 
increased uptake of plasma LDL-C into the β cell [118]. 
The increased amount of cholesterol within the cell 
causes interference with translocation of glucokinase, to 
the mitochondria [119]. A decreased glucose transporter 
(GLUT2) expression level was observed in simvastatin 
treated mouse MIN6 cells which resulted in a reduction 
of ATP levels, inhibition of the  KATP channel closure, 
membrane depolarization and calcium channel open-
ing all leading to reduced insulin secretion [120]. The 
Fig. 5 Schematic representation of the mechanisms of statins related 
to an increased EGP
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ATP-binding cassette transporter ABCA1 could also play 
an important role since a relation was discovered between 
ABCA1 deficiency and an impaired insulin secretion in 
the β cell [121]. Inhibition of the ATP-dependent potas-
sium channel, depolarization and the decreased influx of 
calcium, and intracellular calcium concentrations were 
observed and were related to a decreased insulin secre-
tion [122]. However, intracellular calcium levels were not 
affected in an ex  vivo study wherein intact single-islets 
were treated with simvastatin [123].
Mouse MIN6 β cells treated with simvastatin (14.3 μM) 
showed inhibition of GPR40 (fatty acid receptor), and 
minor inhibition of GLP-1 resulting in a cascade of reac-
tions leading to a decreased insulin secretion [122]. 
Atorvastatin treatment of rat INS-1 β cells induced inhi-
bition of insulin synthesis by inhibiting farnesyl pyroph-
osphate ester (FPP, an intermediate in mevalonate and 
non-mevalonate pathways), which may inhibit a chain of 
proteins that communicates signals from the receptor to 
the nucleus and is called the Ras pathway (Ras/Raf/ERK/
CREB) [124]. Inhibition of this pathway leads to inhibition 
of promoter activity of the insulin gene and to a decrease 
of insulin secretion [124]. Insulin secretion may also be 
impaired via direct statin induced inhibition of mitochon-
drial oxidative phosphorylation at complex III [125]. The 
resulting decrease in ATP synthesis may induce inhibition 
of insulin secretion via the cascade described above.
An interesting observation is that simvastatin treat-
ment (40 mg/day; 6 weeks) in 148 patients resulted in a 
decreased β cell function (53%) and an increased insu-
lin resistance (54%) [126]. One of the mechanisms of 
an increased insulin resistance could be the effect on 
the glucose transporter GLUT-4 located in adipose tis-
sue and muscle. Atorvastatin treatment was shown to 
reduce the surface expression of GLUT-4 in mice adi-
pocytes by inhibiting isoprenylation via inhibition of 
the mevalonate pathway [127]. Mevalonate is an impor-
tant intermediate in cholesterol synthesis and hence also 
for the synthesis of isoprenoid intermediates (Ras and 
Rho proteins important in cell proliferation). These are 
involved in intracellular mobilization and localization of 
proteins. Statin treatment may cause inactivation of Ras 
and Rho molecules so that activation and membrane 
translocalization of GLUT-4 is inhibited. Experiments 
in mouse adipocytes confirmed that GLUT-4 located on 
the plasma membrane moved to the cytosol during ator-
vastatin treatment [128]. This may result in an increased 
insulin resistance.
In conclusion, statin treatment may lead to a decreased 
insulin secretion in the β cell via several mechanisms. 
However, these effects are up to now mainly seen in (ani-
mal) in  vitro studies and so it remains elusive whether 
these results can be translated to humans. In addition, 
it should also be kept in mind that 10  years of statin 
Fig. 6 Hypothetical mechanisms related to a decreased insulin secretion in β cells induced by statins
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treatment in patients caused an increased BMI (1.3  kg/
m2 vs 0.4  kg/m2 in non-users) [129], and BMI is linked 
to insulin resistance which is an important factor in 
developing T2DM. It is not clear whether the patients 
that developed T2DM on statin treatment increased 
their BMI excessively. This is in contrast with metformin. 
Metformin treated mice showed a decreased weight 
gain which was related to the increased energy consum-
ing conversion of glucose to lactate in the intestinal wall 
[130].
Metformin–statin combination therapy
In diabetic rats (200–220  g) it was shown that after 
2  weeks metformin–atorvastatin combination therapy 
(500  mg metformin and 20  mg atorvastatin per 70  kg 
body weight), glucose-lowering effects, lipid-lowering 
effects, reduction of oxidative stress, and positive effects 
on cardiovascular hypertrophy occurred [131]. The 
reduction of oxidative stress and protection of the liver 
(observed by studying the liver histology and blood meas-
urement, e.g. CRP, TNF-α, IL-6, protein carbonyl lev-
els) was also seen in T2DM rats treated with metformin 
and atorvastatin [132, 133]. These positive effects and 
the fact that a great number of patients are treated with 
Metformin–statin combination therapy led to the design 
of a metformin–atorvastatin combination tablet used 
as a single daily dose [134, 135]. There is only a minor 
chance for toxic drug interactions when metformin and 
statin are administered together because metformin is 
not metabolised and most statins are metabolised via the 
cytochrome P450 system [136].
Patients with T2DM are often taking metformin and 
statins together to control CVD risk as well as glucose 
metabolism [82]. Since metformin shows beneficial 
effects on both dyslipidemia and glycemic control and 
has been shown to reduce CVD risk while statins may 
have an added beneficial effect on CVD risk, combined 
treatment with both drugs seems a good option. As far 
as we have been able to discern no randomised clinical 
trials have been carried out to establish whether combi-
nation therapy is superior to monotherapy when focusing 
on CVD risk. Ethical considerations maybe prohibitive 
in this respect but perhaps subgroup analysis in ongo-
ing studies such as the DDPOS may provide an answer. 
Studies aiming at optimal dosing of both drugs have not 
been performed. Clinical studies on the effects of met-
formin and statin combination therapy have been car-
ried out but for different purposes [82, 137–143]. Each 
of these studies had different objectives and included 
different patients groups, i.e. either with T2DM, dyslipi-
demia, treated (different doses), untreated, or newly diag-
nosed T2DM. This precludes comparing these studies to 
arrive at overall results of metformin statin combination 
therapy.
Table  5 shows the glucose and lipid parameters after 
different doses combination therapy in mixed groups of 
patients (impaired fasting glucose (IFG)/dyslipidemia/
T2DM). These studies are now discussed briefly to obtain 
knowledge about the overall effects on glucose and 
lipid metabolism in T2DM patients with dyslipidemia 
(Table  5). Surprisingly, the lowest dose of metformin 
(500 mg) and atorvastatin (10 mg) once daily resulted in 
the highest reduction of fasting plasma glucose (− 35%). 
Atorvastatin 20  mg showed to attenuate the glucose- 
and HbA1c-lowering effect in combination with 1000 
and 2000  mg metformin. A high daily dose of simvas-
tatin (40  mg) and metformin (3000  mg) resulted in an 
improved insulin resistance, but fasting plasma glucose 
decreased only by 5%, and minor changes were observed 
on lipid metabolism parameters, but this was prob-
ably due to the fact that metformin was given on top of 
simvastatin treatment. The patients in these studies had 
different diseased states, such as an impaired fasting glu-
cose, dyslipidemia, newly diagnosed T2DM and/or dys-
lipidemia. This may complicate analysis of the obtained 
changes on the glucose and lipid metabolism. However, 
it could be used for hypothesis-generation rather than 
making rigid decisions, considering the lack of multiple 
dose dependent combination studies.
The effects of metformin on lipid homeostasis as dis-
cussed in this review article, indicate that lipid metabo-
lism is positively affected in the intestine and liver leading 
to decreased plasma triglycerides, LDL-C, and total cho-
lesterol. Metformins effects on lipid metabolism seem to 
be localized to the intestine. Statins mainly act on plasma 
cholesterol levels via activation of the LDL-receptor 
suggesting that combination therapy should show an 
additional effect on plasma lipids. However, the data in 
Table 5 give little indication for an added beneficial effect 
of both drugs on lipid parameters. Dedicated studies are 
required to further investigate the effects of both drugs 
by combination therapy in humans. Metformin has been 
shown to exert a significant influence on the composition 
of the gut microbiota. Interestingly, statins showed such 
effects as well, particularly in studies with mice and rats 
[144, 145]. Statins were able to decrease the production 
of butyrate which may relate to the development of new 
onset T2DM [144]. Atorvastatin given to hypercholes-
terolemic patients restored anti-inflammatory bacteria 
[146].
Combination therapy with statins and metformin 
demonstrated beneficial effects in patients with other 
disease(s)/disorder(s) than T2DM and dyslipidemia. In 
T2DM patients with non-alcoholic fatty liver disease 
(NAFLD) beneficial use of combination therapy seems 
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indicated since statin therapy associates negatively with 
non-alcoholic steatohepatitis and significant fibrosis 
while a safe use of metformin in patients with T2DM 
and NAFLD was demonstrated [147]. Combination 
therapy consisting of metformin and statin treatment is 
frequently prescribed to women with an endocrine dis-
order called polycystic ovary syndrome (PCOS). PCOS 
increases the risk of T2DM and cardiovascular morbid-
ity as it is associated with abnormal increased lipid levels, 
insulin resistance, systemic inflammation and endothelial 
dysfunction [148]. Meta-analysis showed that combined 
statin-metformin therapy in women with PCOS resulted 
in improved lipid and inflammation markers but it did 
not improve insulin sensitivity [149]. Additional studies 
are recommended to confirm these results. Combina-
tion therapy could also be considered for T2DM patients 
with diabetic retinopathy. Diabetic retinopathy (DR) is a 
microvascular complication of diabetes caused by hyper-
glycemia and hyperosmolarity. Leakage and accumula-
tion of fluid in the macula is known as macular edema 
and results in severe vision loss in DR patients. The use of 
statins in T2DM patients and pre-existing DR showed a 
protective effect against development of diabetic macular 
edema [150].
Remarkable is that T2DM patients receiving statin 
therapy in combination with increased levels of choles-
terol remnants and triglycerides were associated with 
slight decreased in left ventricular systolic function. 
Targeting cholesterol remnants in addition to T2DM 
patients receiving statins might be beneficial on cardiac 
function [151]. From a clinical perspective, it was shown 
that many patients with T2DM and CVD did not receive 
lipid lowering therapy while their lipid levels were not 
in the optimal range [152]. Increased implementation 
of guideline recommendations for dyslipidemic T2DM 
patients is therefore recommended [152].
Conclusion
Metformin is generally thought to exert its beneficial 
effects on glucose metabolism mainly in the liver. In 
line with recent literature on the topic we conclude that 
the drug acts primarily in the intestine. This is due to 
the at least one order of magnitude higher concentra-
tions of metformin in the intestine than in the liver. The 
drug is certainly not absent in the liver hence parts of 
its effects may be localized to this organ most probably 
via its effects on gluconeogenesis. To treat T2DM and 
its cardiovascular comorbidity combination therapy 
of metformins with statins seems well placed and may 
act as a double-sided sword particularly in the case of 
statins. This drug increases the risk on T2DM particu-
larly in prediabetic subjects, and cotreatment with met-
formin might reduce this risk. However, this hypothesis 
has not yet been systematically verified. In this review, 
we have investigated possible sites of interaction of 
metformin and statins and conclude that they act on 
largely parallel pathways. Statins reduce plasma choles-
terol via activation of LDL-C receptor in the liver and 
may influence glucose homeostasis primarily by inhibi-
tion of insulin secretion in pancreatic β cells. We pro-
pose that combination therapy will ameliorate the risk 
of statin induced T2DM. More studies of combined 
Metformin–statin treatment in patients are necessary 
to explain the effects of different Metformin–statin 
doses on the glucose and lipid metabolism, in different 
stages of progression of diabetes and/or dyslipidemia, 
in more detail.
Abbreviations
ABCA1: ATP-binding cassette transporter/cholesterol efflux regulatory 
protein (CERP); ACAT : Acyl-CoA cholesterol acyltransferase; ACC1: acetyl-CoA 
carboxylase; ASBT: apical sodium-dependent bile acid transporter; BA: bile 
acids; BMI: body mass index; CAMK2: calcium–calmodulin dependent kinase 
2; CREB: cAMP response element binding protein; CVD: cardiovascular disease; 
DI: disposition indice; DR: diabetic retinopathy; EGP: endogenous glucose 
production; FADS: fatty acid desaturase; FAS: fatty acid synthase; FFA: free fatty 
acid; FGF: fibroblast growth factor; FPP: farnesyl pyrophosphate; FXR: farnesoid 
X receptor; G6Pase: glucose-6-phosphatase; GLP-1: glucagon-like peptide-1; 
GLPR: GLP-1 receptor; GLUT: glucose transporter; GSK-3b: glycogen synthase 
kinase 3; HbA1c: glycated hemoglobin; HDL-C: high-density lipoprotein 
cholesterol; HMGCR : 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase; 
HMGCS: HMG-CoA synthase; HOMA-IR: homeostasis model assessment of 
insulin resistance; IFG: impaired fasting glucose; iNOS: inducible NOS; IRS2: 
insulin receptor substrate 2; JNK: c-jun N-terminal kinase; LDL-C: low-density 
lipoprotein; mGPD: mitochondrial glycerol-3-phosphate dehydrogenase; 
NMDA: N-methyl-d-aspartate; ncNOS: neuronal constitutive NO synthase; NO: 
nitric oxide; NOS: NO synthase; OCT: organic cation transporter; PDX: insulin 
promoter factor; PEPCK: phosphoenolpyruvate carboxykinase; PI3K: phospho-
inositide 3 kinase; PKA: protein kinase A; PKB/AKT: protein kinase B; PMAT: 
plasma monoamine transporter; PP2CA: protein phosphatase 2CA; PSRE: PXR–
SGK2 response elements; PXR: pregnane X receptor; RXR: retinoid X receptor; 
SERT: sodium-dependent serotonin transporter; SGK: serum/glucocorticoid 
regulated kinase; SGLT: sodium/glucose cotransporter; SREBP: sterol regulatory 
element-binding protein; T2DM: type 2 diabetes mellitus; TCF4L2: transcription 
factor 7-like 2; TG: triglycerides; TGR5: G protein-coupled bile acid receptor 1; 
THTR: thiamine transporter.
Authors’ contributions
MFvS wrote the manuscript. AAdG and AKG provided critical discussion 
and feedback on the manuscript. All authors read and approved the final 
manuscript.
Author details
1 Netherlands Organisation for Applied Scientific Research (TNO), Zeist, The 
Netherlands. 2 Amsterdam Diabetes Center and Department of Vascular Medi-
cine, Academic Medical Center, Amsterdam, The Netherlands. 3 Department 
of Laboratory Medicine, University of Groningen, University Medical Center 
Groningen, Groningen, The Netherlands. 
Acknowledgements
We thank S. Meijnikman and VW Bloks for critically reading the manuscript.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Not applicable.
Page 18 of 22van Stee et al. Cardiovasc Diabetol  (2018) 17:94 
Consent for publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Funding
This work was supported by European Union Grant FP7-HEALTH No. 305707 
(RESOLVE).
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 29 March 2018   Accepted: 20 June 2018
References
 1. Bosi E. Metformin—the gold standard in type 2 diabetes: what does the 
evidence tell us? Diabetes Obes Metab. 2009;11(Suppl 2):3–8.
 2. Wu L, Parhofer KG. Diabetic dyslipidemia. Metabolism. 
2014;63(12):1469–79.
 3. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American 
Heart A, National Heart L, Blood I. Definition of metabolic syndrome: 
report of the National Heart, Lung, and Blood Institute/American Heart 
Association conference on scientific issues related to definition. Circula-
tion. 2004;109(3):433–8.
 4. Kitao N, Miyoshi H, Furumoto T, Ono K, Nomoto H, Miya A, Yamamoto 
C, Inoue A, Tsuchida K, Manda N, et al. The effects of vildagliptin com-
pared with metformin on vascular endothelial function and metabolic 
parameters: a randomized, controlled trial (Sapporo Athero-Incretin 
Study 3). Cardiovasc Diabetol. 2017;16(1):125.
 5. Mortensen MB, Kulenovic I, Falk E. Statin use and cardiovascular risk 
factors in diabetic patients developing a first myocardial infarction. 
Cardiovasc Diabetol. 2016;15(1):81.
 6. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Sesha-
sai SR, McMurray JJ, Freeman DJ, Jukema JW, et al. Statins and risk of 
incident diabetes: a collaborative meta-analysis of randomised statin 
trials. Lancet. 2010;375(9716):735–42.
 7. Corrao G, Ibrahim B, Nicotra F, Soranna D, Merlino L, Catapano AL, 
Tragni E, Casula M, Grassi G, Mancia G. Statins and the risk of diabetes: 
evidence from a large population-based cohort study. Diabetes Care. 
2014;37(8):2225–32.
 8. Fischer J, Ganellin CR, Ganesan A, Proudfoot J. Standalone drugs. In: 
Ganellin JFACR, editor. Analogue-based drug discovery. Weinheim: 
Wiley-VCH Verlag GmbH & Co; 2010.
 9. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacoki-
netics of a novel extended-release metformin formulation. Clin Pharma-
cokinet. 2005;44(7):721–9.
 10. Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, 
Fineman M. The primary glucose-lowering effect of metformin resides 
in the gut, not the circulation: results from short-term pharmacokinetic 
and 12-week dose-ranging studies. Diabetes Care. 2016;39(2):198–205.
 11. Hashimoto Y, Tanaka M, Okada H, Mistuhashi K, Kimura T, Kitagawa N, 
Fukuda T, Majima S, Fukuda Y, Tanaka Y, et al. Postprandial hyperglyce-
mia was ameliorated by taking metformin 30 min before a meal than 
taking metformin with a meal; a randomized, open-label, crossover 
pilot study. Endocrine. 2016;52(2):271–6.
 12. Hernandez B, Pfluger F, Kruglik SG, Cohen R, Ghomi M. Protonation-
deprotonation and structural dynamics of antidiabetic drug metformin. 
J Pharm Biomed Anal. 2015;114:42–8.
 13. Bretnall AE, Clarke GS. Metformin hydrochloride. Anal Profiles Drug 
subst Excipients. 1998;25:243–93.
 14. Orgovan G, Noszal B. Electrodeless, accurate pH determination in 
highly basic media using a new set of (1)H NMR pH indicators. J Pharm 
Biomed Anal. 2011;54(5):958–64.
 15. Wilcock C, Wyre ND, Bailey CJ. Subcellular distribution of metformin in 
rat liver. J Pharm Pharmacol. 1991;43(6):442–4.
 16. Wiernsperger NF. Membrane physiology as a basis for the cellular 
effects of metformin in insulin resistance and diabetes. Diabetes Metab. 
1999;25(2):110–27.
 17. Kinaan M, Ding H, Triggle CR. Metformin: an old drug for the treatment 
of diabetes but a new drug for the protection of the endothelium. Med 
Princ Pract. 2015;24(5):401–15.
 18. Bridges HR, Sirvio VA, Agip AN, Hirst J. Molecular features of biguanides 
required for targeting of mitochondrial respiratory complex I and 
activation of AMP-kinase. BMC Biol. 2016;14:65.
 19. Chien HC, Zur AA, Maurer TS, Yee SW, Tolsma J, Jasper P, Scott DO, 
Giacomini KM. Rapid method to determine intracellular drug concen-
trations in cellular uptake assays: application to metformin in organic 
cation transporter 1-transfected human embryonic kidney 293 cells. 
Drug Metab Dispos. 2016;44(3):356–64.
 20. He L, Wondisford FE. Metformin action: concentrations matter. Cell 
Metab. 2015;21(2):159–62.
 21. Wilcock C, Bailey CJ. Sites of metformin-stimulated glucose metabolism. 
Biochem Pharmacol. 1990;39(11):1831–4.
 22. Gormsen LC, Sundelin EI, Jensen JB, Vendelbo MH, Jakobsen S, Munk 
OL, Christensen MM, Brosen K, Frokiaer J, Jessen N. In vivo imaging of 
human 11C-metformin in peripheral organs: dosimetry, biodistribution 
and kinetic analyses. J Nucl Med. 2016;57(12):1920–6.
 23. Han TK, Proctor WR, Costales CL, Cai H, Everett RS, Thakker DR. Four 
cation-selective transporters contribute to apical uptake and accumula-
tion of metformin in Caco-2 cell monolayers. J Pharmacol Exp Ther. 
2015;352(3):519–28.
 24. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal 
tract. Diabetologia. 2016;59(3):426–35.
 25. Liang X, Chien HC, Yee SW, Giacomini MM, Chen EC, Piao M, Hao J, 
Twelves J, Lepist EI, Ray AS, et al. Metformin is a substrate and inhibitor 
of the human thiamine transporter, THTR-2 (SLC19A3). Mol Pharm. 
2015;12(12):4301–10.
 26. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-
stimulated organic cation transporter (plasma membrane monoam-
ine transporter) expressed in human intestine. Drug Metab Dispos. 
2007;35(10):1956–62.
 27. Dujic T, Zhou K, Donnelly LA, Tavendale R, Palmer CN, Pearson ER. Asso-
ciation of organic cation transporter 1 with intolerance to metformin in 
type 2 diabetes: a GoDARTS study. Diabetes. 2015;64(5):1786–93.
 28. Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug 
specificity and intestinal membrane localization of human organic 
cation transporters (OCT). Biochem Pharmacol. 2005;70(12):1851–60.
 29. Proctor WR, Ming X, Bourdet D, Han TK, Everett RS, Thakker DR. Why 
does the intestine lack basolateral efflux transporters for cationic com-
pounds? A provocative hypothesis. J Pharm Sci. 2016;105(2):484–96.
 30. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabeto-
logia. 2008;51(8):1552–3.
 31. Duez H, Lamarche B, Uffelman KD, Valero R, Cohn JS, Lewis GF. Hyper-
insulinemia is associated with increased production rate of intestinal 
apolipoprotein B-48-containing lipoproteins in humans. Arterioscler 
Thromb Vasc Biol. 2006;26(6):1357–63.
 32. Xiao C, Dash S, Morgantini C, Adeli K, Lewis GF. Gut peptides are 
novel regulators of intestinal lipoprotein secretion: experimental and 
pharmacological manipulation of lipoprotein metabolism. Diabetes. 
2015;64(7):2310–8.
 33. Gutierrez-Repiso C, Rodriguez-Pacheco F, Garcia-Arnes J, Valdes S, Gon-
zalo M, Soriguer F, Moreno-Ruiz FJ, Rodriguez-Cañete A, Gallego-Perales 
JL, Alcain-Martinez G. The expression of genes involved in jejunal lipo-
genesis and lipoprotein synthesis is altered in morbidly obese subjects 
with insulin resistance. Lab Invest. 2015;95(12):1409–17.
 34. Jeppesen J, Zhou MY, Chen YD, Reaven GM. Effect of metformin on 
postprandial lipemia in patients with fairly to poorly controlled NIDDM. 
Diabetes Care. 1994;17(10):1093–9.
 35. Field FJ, Born E, Murthy S, Mathur SN. Gene expression of sterol regula-
tory element-binding proteins in hamster small intestine. J Lipid Res. 
2001;42(1):1–8.
 36. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, Yada 
M, Yada R, Harada N, Enjoji M, et al. SREBP-1c, regulated by the insulin 
and AMPK signaling pathways, plays a role in nonalcoholic fatty liver 
disease. Int J Mol Med. 2008;21(4):507–11.
Page 19 of 22van Stee et al. Cardiovasc Diabetol  (2018) 17:94 
 37. Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC, Cramer CT, 
Newton RS. AMP-activated protein kinase: an emerging drug target 
to regulate imbalances in lipid and carbohydrate metabolism to treat 
cardio-metabolic diseases. J Lipid Res. 2012;53(12):2490–514.
 38. Tso P, Sun W, Liu M. Gastrointestinal satiety signals IV. Apolipoprotein 
A-IV. Am J Physiol Gastrointest Liver Physiol. 2004;286(6):G885–90.
 39. Lutz TA, Osto E. Glucagon-like peptide-1, glucagon-like peptide-2, 
and lipid metabolism. Curr Opin Lipidol. 2016;27(3):257–63.
 40. Dash S, Xiao C, Morgantini C, Lewis GF. New insights into the regula-
tion of chylomicron production. Annu Rev Nutr. 2015;35:265–94.
 41. Harmel E, Grenier E, Bendjoudi Ouadda A, El Chebly M, Ziv E, Beaulieu 
JF, Sane A, Spahis S, Laville M, Levy E. AMPK in the small intestine 
in normal and pathophysiological conditions. Endocrinology. 
2014;155(3):873–88.
 42. Rajas F, Bruni N, Montano S, Zitoun C, Mithieux G. The glucose-6 
phosphatase gene is expressed in human and rat small intestine: 
regulation of expression in fasted and diabetic rats. Gastroenterology. 
1999;117(1):132–9.
 43. Mithieux G, Gautier-Stein A. Intestinal glucose metabolism revisited. 
Diabetes Res Clin Pract. 2014;105(3):295–301.
 44. Soty M, Penhoat A, Amigo-Correig M, Vinera J, Sardella A, Vullin-Bouil-
loux F, Zitoun C, Houberdon I, Mithieux G. A gut-brain neural circuit 
controlled by intestinal gluconeogenesis is crucial in metabolic 
health. Mol Metab. 2015;4(2):106–17.
 45. Mithieux G, Rajas F, Zitoun C. Glucose utilization is suppressed in the 
gut of insulin-resistant high fat-fed rats and is restored by metformin. 
Biochem Pharmacol. 2006;72(12):1757–62.
 46. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Suna-
gawa S, Prifti E, Vieira-Silva S, Gudmundsdottir V, Krogh Pedersen H, 
et al. Disentangling type 2 diabetes and metformin treatment signa-
tures in the human gut microbiota. Nature. 2015;528(7581):262–6.
 47. Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, 
Stahlman M, Olsson LM, Serino M, Planas-Felix M, et al. Metformin 
alters the gut microbiome of individuals with treatment-naive type 
2 diabetes, contributing to the therapeutic effects of the drug. Nat 
Med. 2017. https ://doi.org/10.1038/nm.4345.
 48. Duca FA, Cote CD, Rasmussen BA, Zadeh-Tahmasebi M, Rutter GA, 
Filippi BM, Lam TK. Metformin activates a duodenal Ampk-depend-
ent pathway to lower hepatic glucose production in rats. Nat Med. 
2015;21(5):506–11.
 49. Hardie DG. AMP-activated protein kinase: a master switch in glucose 
and lipid metabolism. Rev Endocr Metab Disord. 2004;5(2):119–25.
 50. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK activation: 
a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes. 
2014;7:241–53.
 51. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK, insu-
lin resistance, and the metabolic syndrome. J Clin Invest. 
2013;123(7):2764–72.
 52. Sandoval DA, D’Alessio DA. Physiology of proglucagon peptides: 
role of glucagon and GLP-1 in health and disease. Physiol Rev. 
2015;95(2):513–48.
 53. Habener JF, Kieffer TJ. Glucagon and glucagon-like peptides, chap. 11. 
In: Ronald Kahn C, et al., editors. Joslin’s diabetes mellitus. Philadel-
phia: Lippincott Williams & Wilkins; 2005.
 54. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pez-
zatini A, Brogi M, Dicembrini I, Cremasco F, et al. Effects of metformin 
on glucagon-like peptide-1 levels in obese patients with and without 
type 2 diabetes. Diabetes Nutr Metab. 2004;17(6):336–42.
 55. Napolitano A, Miller S, Nicholls AW, Baker D, Van Horn S, Thomas E, 
Rajpal D, Spivak A, Brown JR, Nunez DJ. Novel gut-based pharmacol-
ogy of metformin in patients with type 2 diabetes mellitus. PLoS 
ONE. 2014;9(7):e100778.
 56. Preiss D, Dawed A, Welsh P, Heggie A, Jones AG, Dekker J, Koivula R, 
Hansen TH, Consortium D, Stewart MC, et al. The sustained influence 
of metformin therapy on circulating GLP-1 levels in individuals with 
and without type 2 diabetes. Diabetes Obes Metab. 2016. https ://doi.
org/10.1111/dom.12826 .
 57. Rohde U, Sonne DP, Christensen M, Hansen M, Bronden A, Torang 
S, Rehfeld JF, Holst JJ, Vilsboll T, Knop FK. Cholecystokinin-induced 
gallbladder emptying and metformin elicit additive glucagon-like 
peptide-1 responses. J Clin Endocrinol Metab. 2016;101(5):2076–83.
 58. Kim MH, Jee JH, Park S, Lee MS, Kim KW, Lee MK. Metformin enhances 
glucagon-like peptide 1 via cooperation between insulin and Wnt 
signaling. J Endocrinol. 2014;220(2):117–28.
 59. Liu YX, Si MM, Lu W, Zhang LX, Zhou CX, Deng SL, Wu HS. Effects and 
molecular mechanisms of the antidiabetic fraction of Acorus calamus L. 
on GLP-1 expression and secretion in vivo and in vitro. J Ethnopharma-
col. 2015;166:168–75.
 60. Trabelsi MS, Daoudi M, Prawitt J, Ducastel S, Touche V, Sayin SI, Perino 
A, Brighton CA, Sebti Y, Kluza J, et al. Farnesoid X receptor inhibits 
glucagon-like peptide-1 production by enteroendocrine L cells. Nat 
Commun. 2015;6:7629.
 61. Jensen JB, Sundelin EI, Jakobsen S, Gormsen LC, Munk OL, Frokiaer 
J, Jessen N. [11C]-Labeled metformin distribution in the liver and 
small intestine using dynamic positron emission tomography in mice 
demonstrates tissue-specific transporter dependency. Diabetes. 
2016;65(6):1724–30.
 62. Zamek-Gliszczynski MJ, Bao JQ, Day JS, Higgins JW. Metformin 
sinusoidal efflux from the liver is consistent with negligible biliary 
excretion and absence of enterohepatic cycling. Drug Metab Dispos. 
2013;41(11):1967–71.
 63. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt 
circulation and intestinal motility in type 2 diabetes mellitus. Diabet 
Med. 1998;15(8):651–6.
 64. Ryan P, Delzenne N. Gut microbiota and metabolism. In: Hyland N, 
Stanton C, editors. The Gut-Brain axis. New York: Elsevier; 2016.
 65. Wang Z, Koonen D, Hofker M, Fu J. Gut microbiome and lipid 
metabolism: from associations to mechanisms. Curr Opin Lipidol. 
2016;27(3):216–24.
 66. Wahlstrom A, Sayin SI, Marschall HU, Backhed F. Intestinal crosstalk 
between bile acids and microbiota and its impact on host metabolism. 
Cell Metab. 2016;24(1):41–50.
 67. de la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, Velásquez-Mejía 
EP, Carmona JA, Abad JM, Escobar JS. Metformin is associated with 
higher relative abundance of mucin-degrading Akkermansia mucin-
iphila and several short-chain fatty acid-producing microbiota in the 
gut. Diabetes Care. 2016. https ://doi.org/10.2337/dc16-1324.
 68. Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E, Verger EO, 
Kayser BD, Levenez F, Chilloux J, Hoyles L, et al. Akkermansia mucin-
iphila and improved metabolic health during a dietary intervention in 
obesity: relationship with gut microbiome richness and ecology. Gut. 
2016;65(3):426–36.
 69. Zhou K, Pedersen HK, Dawed AY, Pearson ER. Pharmacogenomics in 
diabetes mellitus: insights into drug action and drug discovery. Nat Rev 
Endocrinol. 2016;12(6):337–46.
 70. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. 
Involvement of organic cation transporter 1 in hepatic and intestinal 
distribution of metformin. J Pharmacol Exp Ther. 2002;302(2):510–5.
 71. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from 
mechanisms of action to therapies. Cell Metab. 2014;20(6):953–66.
 72. Gruszka A. New insight into the mechanisms of the anti-hyperglycemic 
action of metformin. Br J Med Med Res. 2016;13:1–9.
 73. Baur JA, Birnbaum MJ. Control of gluconeogenesis by metformin: does 
redox trump energy charge? Cell Metab. 2014;20(2):197–9.
 74. Viollet B, Guigas B, Leclerc J, Hebrard S, Lantier L, Mounier R, Andreelli 
F, Foretz M. AMP-activated protein kinase in the regulation of hepatic 
energy metabolism: from physiology to therapeutic perspectives. Acta 
Physiol (Oxf ). 2009;196(1):81–98.
 75. Madsen A, Bozickovic O, Bjune JI, Mellgren G, Sagen JV. Metformin 
inhibits hepatocellular glucose, lipid and cholesterol biosynthetic 
pathways by transcriptionally suppressing steroid receptor coactivator 
2 (SRC-2). Sci Rep. 2015;5:16430.
 76. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, 
Doebber T, Fujii N, et al. Role of AMP-activated protein kinase in mecha-
nism of metformin action. J Clin Invest. 2001;108(8):1167–74.
 77. Maziere JC, Maziere C, Mora L, Gardette J, Salmon S, Auclair M, Polo-
novski J. The antidiabetic drug metformin decreases cholesterol metab-
olism in cultured human fibroblasts. Atherosclerosis. 1988;71(1):27–33.
 78. Koren-Gluzer M, Aviram M, Hayek T. Metformin inhibits macrophage 
cholesterol biosynthesis rate: possible role for metformin-induced 
oxidative stress. Biochem Biophys Res Commun. 2013;439(3):396–400.
Page 20 of 22van Stee et al. Cardiovasc Diabetol  (2018) 17:94 
 79. Liu ZQ, Song XM, Chen QT, Liu T, Teng JT, Zhou K, Luo DQ. Effect of 
metformin on global gene expression in liver of KKAy mice. Pharmacol 
Rep. 2016;68(6):1332–8.
 80. Scott LM, Tomkin GH. Changes in hepatic and intestinal cholesterol 
regulatory enzymes. The influence of metformin. Biochem Pharmacol. 
1983;32(5):827–30.
 81. Chakraborty A, Chowdhury S, Bhattacharyya M. Effect of metformin on 
oxidative stress, nitrosative stress and inflammatory biomarkers in type 
2 diabetes patients. Diabetes Res Clin Pract. 2011;93(1):56–62.
 82. Kashi Z, Mahrooz A, Kianmehr A, Alizadeh A. The role of metformin 
response in lipid metabolism in patients with recent-onset type 2 dia-
betes: HbA1c level as a criterion for designating patients as responders 
or nonresponders to metformin. PLoS ONE. 2016;11(3):e0151543.
 83. Ohira M, Miyashita Y, Ebisuno M, Saiki A, Endo K, Koide N, Oyama T, 
Murano T, Watanabe H, Shirai K. Effect of metformin on serum lipopro-
tein lipase mass levels and LDL particle size in type 2 diabetes mellitus 
patients. Diabetes Res Clin Pract. 2007;78(1):34–41.
 84. Zhang C, Gao F, Luo H, Zhang CT, Zhang R. Differential response in 
levels of high-density lipoprotein cholesterol to one-year metformin 
treatment in prediabetic patients by race/ethnicity. Cardiovasc Diabe-
tol. 2015;14:79.
 85. Sonne DP, Knop FK. Comment on Xu et al. Effects of metformin on 
metabolite profiles and LDL cholesterol in patients with type 2 diabe-
tes. Diabetes Care 2015;38:1858–1867. Diabetes Care. 2015; 38(12):e215.
 86. Hofmann AF, Hagey LR. Key discoveries in bile acid chemistry and biol-
ogy and their clinical applications: history of the last eight decades. J 
Lipid Res. 2014;55(8):1553–95.
 87. The lipid research clinics coronary primary prevention trial 
results. I. Reduction in incidence of coronary heart disease. JAMA. 
1984;251(3):351–64.
 88. Luo F, Guo Y, Ruan G, Li X. Metformin promotes cholesterol efflux in 
macrophages by up-regulating FGF21 expression: a novel anti-athero-
sclerotic mechanism. Lipids Health Dis. 2016;15:109.
 89. Nygaard EB, Vienberg SG, Orskov C, Hansen HS, Andersen B. Metformin 
stimulates FGF21 expression in primary hepatocytes. Exp Diabetes Res. 
2012;2012:465282.
 90. Fan H, Sun X, Zhang H, Liu J, Zhang P, Xu Y, Pan Q, Wang G. Effect of 
metformin on fibroblast growth factor-21 levels in patients with newly 
diagnosed type 2 diabetes. Diabetes Technol Ther. 2016;18(3):120–6.
 91. Xu T, Brandmaier S, Messias AC, Herder C, Draisma HH, Demirkan A, Yu 
Z, Ried JS, Haller T, Heier M, et al. Effects of metformin on metabolite 
profiles and LDL cholesterol in patients with type 2 diabetes. Diabetes 
Care. 2015;38(10):1858–67.
 92. Sone Y, Kido T, Ainuki T, Sonoda M, Ichi I, Kodama S, Sone H, Kondo K, 
Morita Y, Egawa S, et al. Genetic variants of the fatty acid desaturase 
gene cluster are associated with plasma LDL cholesterol levels in Japa-
nese males. J Nutr Sci Vitaminol (Tokyo). 2013;59(4):325–35.
 93. Zang M, Zuccollo A, Hou X, Nagata D, Walsh K, Herscovitz H, Brecher 
P, Ruderman NB, Cohen RA. AMP-activated protein kinase is required 
for the lipid-lowering effect of metformin in insulin-resistant human 
HepG2 cells. J Biol Chem. 2004;279(46):47898–905.
 94. Wang J, Yang X, Zhang J. Bridges between mitochondrial oxidative 
stress, ER stress and mTOR signaling in pancreatic β cells. Cell Signal. 
2016;28(8):1099–104.
 95. Tanaka K, Saisho Y, Manesso E, Tanaka M, Meguro S, Irie J, Sugiura H, 
Kawai T, Jinzaki M, Cobelli C, et al. Effects of liraglutide monotherapy on 
beta cell function and pancreatic enzymes compared with metformin 
in Japanese overweight/obese patients with type 2 diabetes mellitus: 
a subpopulation analysis of the KIND-LM randomized trial. Clin Drug 
Investig. 2015;35(10):675–84.
 96. Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R. The oral mini-
mal model method. Diabetes. 2014;63(4):1203–13.
 97. Konopka AR, Esponda RR, Robinson MM, Johnson ML, Carter RE, Schi-
avon M, Cobelli C, Wondisford FE, Lanza IR, Nair KS. Hyperglucagonemia 
mitigates the effect of metformin on glucose production in prediabe-
tes. Cell Rep. 2016;15(7):1394–400.
 98. Lupi R, Del Guerra S, Fierabracci V, Marselli L, Novelli M, Patane G, Boggi 
U, Mosca F, Piro S, Del Prato S, et al. Lipotoxicity in human pancreatic 
islets and the protective effect of metformin. Diabetes. 2002;51(Suppl 
1):S134–7.
 99. Natalicchio A, Biondi G, Marrano N, Labarbuta R, Tortosa F, Spagnuolo R, 
D’Oria R, Carchia E, Leonardini A, Cignarelli A, et al. Long-Term exposure 
of pancreatic beta-cells to palmitate results in SREBP-1C-dependent 
decreases in GLP-1 receptor signaling via CREB and AKT and insulin 
secretory response. Endocrinology. 2016;157(6):2243–58.
 100. Dai YL, Huang SL, Leng Y. AICAR and metformin exert AMPK-dependent 
effects on INS-1E pancreatic beta-cell apoptosis via differential down-
stream mechanisms. Int J Biol Sci. 2015;11(11):1272–80.
 101. Chang TJ, Tseng HC, Liu MW, Chang YC, Hsieh ML, Chuang LM. 
Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of 
beta cells through improving mitochondrial function and suppressing 
prolonged AMPK activation. Sci Rep. 2016;6:23403.
 102. Muhammed SJ, Lundquist I, Salehi A. Pancreatic beta-cell dysfunction, 
expression of iNOS and the effect of phosphodiesterase inhibitors 
in human pancreatic islets of type 2 diabetes. Diabetes Obes Metab. 
2012;14(11):1010–9.
 103. Mezghenna K, Pomies P, Chalancon A, Castex F, Leroy J, Niclauss N, 
Nadal B, Cambier L, Cazevieille C, Petit P, et al. Increased neuronal nitric 
oxide synthase dimerisation is involved in rat and human pancreatic 
beta cell hyperactivity in obesity. Diabetologia. 2011;54(11):2856–66.
 104. Lundquist I, Mohammed Al-Amily I, Meidute Abaraviciene S, Salehi 
A. Metformin ameliorates dysfunctional traits of glibenclamide- 
and glucose-induced insulin secretion by suppression of imposed 
overactivity of the islet nitric oxide synthase-NO system. PLoS ONE. 
2016;11(11):e0165668.
 105. Brereton MF, Rohm M, Shimomura K, Holland C, Tornovsky-Babeay S, 
Dadon D, Iberl M, Chibalina MV, Lee S, Glaser B, et al. Hyperglycaemia 
induces metabolic dysfunction and glycogen accumulation in pancre-
atic beta-cells. Nat Commun. 2016;7:13496.
 106. Consortium R. Restoring insulin secretion (RISE): design of studies of 
beta-cell preservation in prediabetes and early type 2 diabetes across 
the life span. Diabetes Care. 2014;37(3):780–8.
 107. Force USPST, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, 
Epling JW Jr, Garcia FA, Gillman MW, Kemper AR, Krist AH, et al. Statin 
use for the primary prevention of cardiovascular disease in adults: 
US preventive services task force recommendation statement. JAMA. 
2016;316(19):1997–2007.
 108. Gruzdeva O, Uchasova E, Dyleva Y, Akbasheva O, Karetnikova V, Shilov A, 
Barbarash O. Effect of different doses of statins on the development of 
type 2 diabetes mellitus in patients with myocardial infarction. Diabetes 
Metab Syndr Obes Targets Ther. 2017;10:481.
 109. Gruzdeva O, Uchasova E, Dyleva Y, Akbasheva O, Karetnikova V, Barbar-
ash O. Early effects of treatment low-dose atorvastatin on markers of 
insulin resistance and inflammation in patients with myocardial infarc-
tion. Front Pharmacol. 2016;7:324.
 110. Anyanwagu U, Idris I, Donnelly R. Drug-induced diabetes mellitus: 
evidence for statins and other drugs affecting glucose metabolism. Clin 
Pharmacol Ther. 2016;99(4):390–400.
 111. Wang S, Cai R, Yuan Y, Varghese Z, Moorhead J, Ruan XZ. Association 
between reductions in low-density lipoprotein cholesterol with statin 
therapy and the risk of new-onset diabetes: a meta-analysis. Sci Rep. 
2017;7:39982.
 112. Gotoh S, Negishi M. Statin-activated nuclear receptor PXR promotes 
SGK2 dephosphorylation by scaffolding PP2C to induce hepatic gluco-
neogenesis. Sci Rep. 2015;5:14076.
 113. Hakkola J, Rysa J, Hukkanen J. Regulation of hepatic energy 
metabolism by the nuclear receptor PXR. Biochim Biophys Acta. 
2016;1859(9):1072–82.
 114. He C, Klionsky DJ. Regulation mechanisms and signaling pathways of 
autophagy. Annu Rev Genet. 2009;43:67–93.
 115. Ling Z, Shu N, Xu P, Wang F, Zhong Z, Sun B, Li F, Zhang M, Zhao K, Tang 
X, et al. Involvement of pregnane X receptor in the impaired glucose 
utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 
2016;100:98–111.
 116. Black RN, Ennis CN, Young IS, Hunter SJ, Atkinson AB, Bell PM. The 
peroxisome proliferator-activated receptor alpha agonist fenofibrate 
has no effect on insulin sensitivity compared to atorvastatin in type 2 
diabetes mellitus; a randomised, double-blind controlled trial. J Diabe-
tes Complications. 2014;28(3):323–7.
 117. Szendroedi J, Anderwald C, Krssak M, Bayerle-Eder M, Esterbauer H, 
Pfeiler G, Brehm A, Nowotny P, Hofer A, Waldhausl W, et al. Effects of 
Page 21 of 22van Stee et al. Cardiovasc Diabetol  (2018) 17:94 
high-dose simvastatin therapy on glucose metabolism and ectopic 
lipid deposition in nonobese type 2 diabetic patients. Diabetes Care. 
2009;32(2):209–14.
 118. Ruscica M, Macchi C, Morlotti B, Sirtori CR, Magni P. Statin therapy and 
related risk of new-onset type 2 diabetes mellitus. Eur J Intern Med. 
2014;25(5):401–6.
 119. Hao M, Head WS, Gunawardana SC, Hasty AH, Piston DW. Direct effect 
of cholesterol on insulin secretion: a novel mechanism for pancreatic 
beta-cell dysfunction. Diabetes. 2007;56(9):2328–38.
 120. Zhou J, Li W, Xie Q, Hou Y, Zhan S, Yang X, Xu X, Cai J, Huang Z. Effects 
of simvastatin on glucose metabolism in mouse MIN6 cells. J Diabetes 
Res. 2014;2014:376570.
 121. Vergeer M, Brunham LR, Koetsveld J, Kruit JK, Verchere CB, Kaste-
lein JJ, Hayden MR, Stroes ES. Carriers of loss-of-function mutations 
in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care. 
2010;33(4):869–74.
 122. Yaluri N, Modi S, Lopez Rodriguez M, Stancakova A, Kuusisto J, Kokkola 
T, Laakso M. Simvastatin impairs insulin secretion by multiple mecha-
nisms in MIN6 cells. PLoS ONE. 2015;10(11):e0142902.
 123. Scattolini V, Luni C, Zambon A, Galvanin S, Gagliano O, Ciubotaru CD, 
Avogaro A, Mammano F, Elvassore N, Fadini GP. Simvastatin rapidly 
and reversibly inhibits insulin secretion in intact single-islet cultures. 
Diabetes Ther. 2016;7(4):679–93.
 124. Sun H, Li Y, Sun B, Hou N, Yang J, Zheng M, Xu J, Wang J, Zhang Y, 
Zeng X, et al. Atorvastatin inhibits insulin synthesis by inhibiting 
the Ras/Raf/ERK/CREB pathway in INS-1 cells. Medicine (Baltimore). 
2016;95(39):e4906.
 125. Schirris TJ, Renkema GH, Ritschel T, Voermans NC, Bilos A, van Engelen 
BG, Brandt U, Koopman WJ, Beyrath JD, Rodenburg RJ, et al. Statin-
induced myopathy is associated with mitochondrial complex iii inhibi-
tion. Cell Metab. 2015;22(3):399–407.
 126. Elbadawi-Sidhu M, Baillie RA, Zhu H, Chen YDI, Goodarzi MO, Rotter JI, 
Krauss RM, Fiehn O, Kaddurah-Daouk R. Pharmacometabolomic sig-
nature links simvastatin therapy and insulin resistance. Metabolomics. 
2017;13(1):11.
 127. Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of atorvas-
tatin and pravastatin on signal transduction related to glucose uptake 
in 3T3L1 adipocytes. J Pharmacol Sci. 2008;107(1):80–9.
 128. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects 
of statins on the adipocyte maturation and expression of glucose 
transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 
2006;49(8):1881–92.
 129. Sugiyama T, Tsugawa Y, Tseng CH, Kobayashi Y, Shapiro MF. Different 
time trends of caloric and fat intake between statin users and nonusers 
among US adults: gluttony in the time of statins? JAMA Intern Med. 
2014;174(7):1038–45.
 130. Schommers P, Thurau A, Bultmann-Mellin I, Guschlbauer M, Klatt AR, 
Rozman J, Klingenspor M, de Angelis MH, Alber J, Gründemann D. Met-
formin causes a futile intestinal—hepatic cycle which increases energy 
expenditure and slows down development of a type 2 diabetes-like 
state. Molecular Metabolism. 2017. https ://doi.org/10.1016/j.molme 
t.2017.05.002.
 131. Islam M, Alam A, Rahman M, Ali Y, Mamun A, Rahman M, Hossain A, 
Rashid M. Effects of combination of antidiabetic agent and statin on 
alloxan-induced diabetes with cardiovascular diseases in rats. J Sci Res. 
2012;4(3):709–20.
 132. Matafome P, Louro T, Rodrigues L, Crisostomo J, Nunes E, Amaral C, 
Monteiro P, Cipriano A, Seica R. Metformin and atorvastatin combina-
tion further protect the liver in type 2 diabetes with hyperlipidaemia. 
Diabetes Metab Res Rev. 2011;27(1):54–62.
 133. Singh BK, Singh A, Kumar V. Ameliorative effect of adjunct therapy of 
metformin with atorvastatin on streptozotocin-induced diabetes mel-
litus in rats. Drug Res (Stuttg). 2016;66(1):28–32.
 134. Oh JH, Eun Lee J, Jeong Kim Y, Oh TO, Han S, Jeon EK, Shin K, Kim DH, 
Hye Park C, Lee YJ. Designing of the fixed-dose gastroretentive bilayer 
tablet for sustained release of metformin and immediate release of 
atorvastatin. Drug Dev Ind Pharm. 2016;42(2):340–9.
 135. Kandhwal K, Dey S, Nazarudheen S, Arora R, Reyar S, Thudi NR, Monif 
T, Singh MK, Rao S. Pharmacokinetics of a fixed-dose combination 
of atorvastatin and metformin extended release versus concurrent 
administration of individual formulations: a randomized, open-label, 
two-treatment, two-period, two-sequence, single-dose, crossover, 
bioequivalence study. Clin Drug Investig. 2011;31(12):853–63.
 136. Scheen AJ. Drug interactions of clinical importance with antihypergly-
caemic agents: an update. Drug Saf. 2005;28(7):601–31.
 137. Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar 
I, Nayak UP, Sharma A, Bolmall C, Baliga VP. Assessment of the efficacy 
and tolerability of a fixed dose combination of atorvastatin 10 mg+ 
metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. 
J Indian Med Assoc. 2008;106(7):464–7.
 138. Krysiak R, Okopien B. Haemostatic effects of metformin in simvastatin-
treated volunteers with impaired fasting glucose. Basic Clin Pharmacol 
Toxicol. 2012;111(6):380–4.
 139. Krysiak R, Okopien B. Lymphocyte-suppressing and systemic 
anti-inflammatory effects of high-dose metformin in simvastatin-
treated patients with impaired fasting glucose. Atherosclerosis. 
2012;225(2):403–7.
 140. Krysiak R, Okopien B. The effect of metformin on monocyte secretory 
function in simvastatin-treated patients with impaired fasting glucose. 
Metabolism. 2013;62(1):39–43.
 141. Tousoulis D, Koniari K, Antoniades C, Papageorgiou N, Miliou A, 
Noutsou M, Nikolopoulou A, Marinou K, Stefanadi E, Siasos G, et al. 
Combined effects of atorvastatin and metformin on glucose-induced 
variations of inflammatory process in patients with diabetes mellitus. 
Int J Cardiol. 2011;149(1):46–9.
 142. Tousoulis D, Koniari K, Antoniades C, Miliou A, Noutsou M, Nikolopou-
lou A, Papageorgiou N, Marinou K, Stefanadi E, Stefanadis C. Impact of 
6 weeks of treatment with low-dose metformin and atorvastatin on 
glucose-induced changes of endothelial function in adults with newly 
diagnosed type 2 diabetes mellitus: a single-blind study. Clin Ther. 
2010;32(10):1720–8.
 143. Hao Z, Liu Y, Liao H, Zheng D, Xiao C, Li G. Atorvastatin plus metformin 
confer additive benefits on subjects with dyslipidemia and overweight/
obese via reducing ROCK2 concentration. Exp Clin Endocrinol Diabetes. 
2016;124(4):246–50.
 144. Caparros-Martin JA, Lareu RR, Ramsay JP, Peplies J, Reen FJ, Headlam 
HA, Ward NC, Croft KD, Newsholme P, Hughes JD, et al. Statin therapy 
causes gut dysbiosis in mice through a PXR-dependent mechanism. 
Microbiome. 2017;5(1):95.
 145. Khan TJ, Ahmed YM, Zamzami MA, Mohamed SA, Khan I, Baothman 
OAS, Mehanna MG, Yasir M. Effect of atorvastatin on the gut micro-
biota of high fat diet-induced hypercholesterolemic rats. Sci Rep. 
2018;8(1):662.
 146. Khan TJ, Ahmed YM, Zamzami MA, Siddiqui AM, Khan I, Baothman 
OAS, Mehanna MG, Kuerban A, Kaleemuddin M, Yasir M. Atorvastatin 
treatment modulates the gut microbiota of the hypercholesterolemic 
patients. OMICS. 2018;22(2):154–63.
 147. Nascimbeni F, Aron-Wisnewsky J, Pais R, Tordjman J, Poitou C, Charlotte 
F, Bedossa P, Poynard T, Clement K, Ratziu V, et al. Statins, antidiabetic 
medications and liver histology in patients with diabetes with non-
alcoholic fatty liver disease. BMJ Open Gastroenterol. 2016;3(1):e000075.
 148. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 
2005;352(12):1223–36.
 149. Sun J, Yuan Y, Cai R, Sun H, Zhou Y, Wang P, Huang R, Xia W, Wang S. An 
investigation into the therapeutic effects of statins with metformin on 
polycystic ovary syndrome: a meta-analysis of randomised controlled 
trials. BMJ Open. 2015;5(3):e007280.
 150. Chung Y-R, Park SW, Choi S-Y, Kim SW, Moon KY, Kim JH, Lee K. Associa-
tion of statin use and hypertriglyceridemia with diabetic macular 
edema in patients with type 2 diabetes and diabetic retinopathy. 
Cardiovasc Diabetol. 2017;16(1):4.
 151. Jorgensen PG, Jensen MT, Biering-Sorensen T, Mogelvang R, Galatius 
S, Fritz-Hansen T, Rossing P, Vilsboll T, Jensen JS. Cholesterol remnants 
and triglycerides are associated with decreased myocardial function in 
patients with type 2 diabetes. Cardiovasc Diabetol. 2016;15(1):137.
 152. Hanefeld M, Traylor L, Gao L, Landgraf W. The use of lipid-lowering 
therapy and effects of antihyperglycaemic therapy on lipids in subjects 
with type 2 diabetes with or without cardiovascular disease: a pooled 
analysis of data from eleven randomized trials with insulin glargine 100 
U/mL. Cardiovasc Diabetol. 2017;16(1):66.
 153. Besseling J, Hutten BA. Is there a link between diabetes and cholesterol 
metabolism? Expert Rev Cardiovasc Ther. 2016;14(3):259–61.
Page 22 of 22van Stee et al. Cardiovasc Diabetol  (2018) 17:94 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
 154. Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. 
Increased risk of diabetes with statin treatment is associated with 
impaired insulin sensitivity and insulin secretion: a 6 year follow-up 
study of the METSIM cohort. Diabetologia. 2015;58(5):1109–17.
 155. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 
diabetes: prevalence, pathophysiology, and management. Drugs. 
2013;73(4):327–39.
 156. Feingold K, Grunfeld C. Role of glucose and lipids in the cardiovascular 
disease of patients with diabetes. In: De Groot LJ, Chrousos G, Dungan 
K, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 
2000.
 157. Jaiswal M, Schinske A, Pop-Busui R. Lipids and lipid management in 
diabetes. Best Pract Res Clin Endocrinol Metab. 2014;28(3):325–38.
 158. Ng DS. Diabetic dyslipidemia: from evolving pathophysiological insight 
to emerging therapeutic targets. Can J Diabetes. 2013;37(5):319–26.
 159. Soran H, Schofield JD, Adam S, Durrington PN. Diabetic dyslipidaemia. 
Curr Opin Lipidol. 2016;27(4):313–22.
 160. Schofield JD, Liu Y, Rao-Balakrishna P, Malik RA, Soran H. Diabetes dys-
lipidemia. Diabetes Ther. 2016;7(2):203–19.
 161. Verges B. Pathophysiology of diabetic dyslipidaemia: where are we? 
Diabetologia. 2015;58(5):886–99.
 162. Wang CCL, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovas-
cular disease in diabetes mellitus atherosclerotic cardiovascular disease 
and heart failure in type 2 diabetes mellitus-mechanisms, manage-
ment, and clinical considerations. Circulation. 2016;133(24):2459–502.
 163. Arca M. Alterations of intestinal lipoprotein metabolism in diabetes 
mellitus and metabolic syndrome. Atheroscler Suppl. 2015;17:12–6.
 164. Tomkin GH, Owens D. Dyslipidaemia of diabetes and the intestine. 
World J Diabetes. 2015;6(7):970–7.
 165. Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: 
relevance for atherogenesis. Curr Vasc Pharmacol. 2012;10(6):684–6.
 166. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic 
lipids in hepatic insulin resistance and type 2 diabetes. Nature. 
2014;510(7503):84–91.
 167. Taskinen MR, Boren J. New insights into the pathophysiology of dyslipi-
demia in type 2 diabetes. Atherosclerosis. 2015;239(2):483–95.
 168. Pagidipati NJ, Pencina M, Sniderman AD. The enigma of glucose and 
lipid metabolism. JAMA Cardiol. 2016;1(2):145–6.
 169. Parhofer KG. Interaction between glucose and lipid metabolism: more 
than diabetic dyslipidemia. Diabetes Metab J. 2015;39(5):353–62.
 170. Patel TP, Rawal K, Bagchi AK, Akolkar G, Bernardes N, Dias Dda S, Gupta 
S, Singal PK. Insulin resistance: an additional risk factor in the patho-
genesis of cardiovascular disease in type 2 diabetes. Heart Fail Rev. 
2016;21(1):11–23.
 171. Dake AW, Sora ND. Diabetic dyslipidemia review: an update on current 
concepts and management guidelines of diabetic dyslipidemia. Am J 
Med Sci. 2016;351(4):361–5.
 172. Halcox J, Misra A. Type 2 diabetes mellitus, metabolic syndrome, and 
mixed dyslipidemia: how similar, how different, and how to treat? 
Metab Syndr Relat Disord. 2015;13(1):1–21.
 173. Paneni F, Cosentino F. Diabetic dyslipidemia. In: Diabetes and cardiovas-
cular disease. Cham: Springer; 2015. p. 101–13.
 174. Szalat A, Durst R, Leitersdorf E. Managing dyslipidaemia in type 2 diabe-
tes mellitus. Best Pract Res Clin Endocrinol Metab. 2016;30(3):431–44.
 175. Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardio-
vascular disease in type 2 diabetes. Eur Heart J. 2015;36(34):2288–96.
 176. Balakumar P. Implications of fundamental signalling alterations in 
diabetes mellitus-associated cardiovascular disease. Indian J Biochem 
Biophys. 2014;51(6):441–8.
 177. Chen SC, Tseng CH. Dyslipidemia, kidney disease, and cardiovascular 
disease in diabetic patients. Rev Diabet Stud. 2013;10(2–3):88–100.
 178. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiol-
ogy, biological mechanisms, treatment recommendations and future 
research. World J Diabetes. 2015;6(13):1246–58.
 179. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular 
disease: pathophysiology, clinical consequences, and medical therapy: 
part I. Eur Heart J. 2013;34(31):2436–43.
 180. Scheen AJ. Will delayed release metformin provide better management 
of diabetes type 2? Expert Opin Pharmacother. 2016;17(5):627–30.
 181. Foster RH, Keam SJ. Metformin extended release. Am J Drug Deliv. 
2006;4(3):177–86.
 182. Ali S, Fonseca V. Overview of metformin: special focus on metformin 
extended release. Expert Opin Pharmacother. 2012;13(12):1797–805.
 183. Campbell I, Clarke B, Duncan L. A clinical evaluation of a delayed release 
preparation of metformin. J Int Med Res. 1973;1(6):551–6.
 184. Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the 
normal and diabetic mouse. Xenobiotica. 1994;24(1):49–57.
